In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

The University of Auckland is hosting the research as part of the Global COVID Vaccine Safety (GCoVS) Project. Scientists ...

The only man in his immediate family to be without a cancer diagnosis, one Lynch syndrome patient made the trip to ...

The recombinant, protein-based vaccine is one of only a handful of acne vaccines worldwide promising alternative treatment.

Sanofi's acquisition of Dynavax, valued at $2.2 billion, aims to enhance its vaccine portfolio, including a promising shingles vaccine candidate, Z-1018. Z-1018 has demonstrated comparable ...

The experimental mRNA-based drug sharply reduced the risk of recurrence or death when combined with immunotherapy Keytruda, ...

ETHealthworld.com brings latest cancer research news, views and updates from all top sources for the Indian Health industry.

Moderna Inc.’s chief executive officer said the company doesn’t plan to invest in new late-stage vaccine trials because of ...

Jan 22 (Reuters) - Moderna does not plan to invest in new late-stage vaccine trials because of growing opposition to ...

If promising results on a skin cancer vaccine from Moderna and Merck lead to a new launch, the Covid-19 era darling's stock ...

By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...